The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.

Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 ...

The U.S. Food and Drug Administration has approved Axsome Therapeutics' Symbravo (meloxicam and rizatriptan) for the acute ...

Propranolol, a beta blocker medication used for treating high blood pressure and preventing migraines, may lower ischemic stroke risk in women who experience migraines frequently.

A medication often used to treat high blood pressure and prevent migraines was associated with a reduction in ischemic stroke risk among women using the drug for migraine prevention, according to a ...

The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's ...

A common drug used to prevent migraines might have an additional benefit -- protecting women against stroke. Women taking the ...

The US Food and Drug Administration FDA has approved Symbravo, an oral combination of meloxicam and rizatriptan, for the ...

The novel formulation of rizatriptan and meloxicam (Symbravo, Axome Therapeutics) is for the acute treatment of migraine with ...

Propranolol's protective effect was found to be more pronounced in women with migraines without aura and for ischemic stroke.